News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
National Center for Research and Development (NCBR) funds OncoArendi Therapeutics’ new research platform of innovative anticancer drugs targeting deubiquitinase proteins.
31 January 2020
First clinical proof-of-concept for arginase inhibitors in cancer immunotherapy
1 October 2019
OncoArendi Therapeutics at the 2019 BIO International Convention in USA
31 May 2019
OncoArendi Therapeutics wins the award of the Stock Exchange “Company of the Year” competition 2018
14 March 2019